BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harbaum L, Rhodes CJ, Otero-Núñez P, Wharton J, Wilkins MR. The application of 'omics' to pulmonary arterial hypertension. Br J Pharmacol 2021;178:108-20. [PMID: 32201940 DOI: 10.1111/bph.15056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Domingo LT, Ivy DD, Abman SH, Grenolds AM, Maclean JT, Breaux JA, Minford KJ, Frank BS. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide. Front Pediatr 2022;10. [DOI: 10.3389/fped.2022.1014922] [Reference Citation Analysis]
2 Sonawane AR, Aikawa E, Aikawa M. Connections for Matters of the Heart: Network Medicine in Cardiovascular Diseases. Front Cardiovasc Med 2022;9:873582. [DOI: 10.3389/fcvm.2022.873582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Welch CL, Chung WK. Genomics of Pulmonary Hypertension. Advances in Pulmonary Hypertension 2021;20:142-149. [DOI: 10.21693/1933-088x-20.5.142] [Reference Citation Analysis]
4 He YY, Yan Y, Chen JW, Liu S, Hua L, Jiang X, Xu XQ, Lu D, Jing ZC, Yan FX, Han ZY. Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease. Acta Pharmacol Sin 2021. [PMID: 34848852 DOI: 10.1038/s41401-021-00804-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Qin X, Li T, Sun W, Guo X, Fang Q. Proteomic analysis of pulmonary arterial hypertension. Ther Adv Chronic Dis 2021;12:20406223211047304. [PMID: 34729151 DOI: 10.1177/20406223211047304] [Reference Citation Analysis]
6 Schulz R, Wilkins M. Pulmonary hypertension with 2020 vision. Br J Pharmacol 2021;178:3-5. [PMID: 33346924 DOI: 10.1111/bph.15328] [Reference Citation Analysis]
7 Pullamsetti SS, Tello K, Seeger W. Utilising biomarkers to predict right heart maladaptive phenotype: a step toward precision medicine. Eur Respir J 2021;57:2004506. [PMID: 33833075 DOI: 10.1183/13993003.04506-2020] [Reference Citation Analysis]
8 Oldham WM, Hemnes AR, Aldred MA, Barnard J, Brittain EL, Chan SY, Cheng F, Cho MH, Desai AA, Garcia JGN, Geraci MW, Ghiassian SD, Hall KT, Horn EM, Jain M, Kelly RS, Leopold JA, Lindstrom S, Modena BD, Nichols WC, Rhodes CJ, Sun W, Sweatt AJ, Vanderpool RR, Wilkins MR, Wilmot B, Zamanian RT, Fessel JP, Aggarwal NR, Loscalzo J, Xiao L. NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:2040-52. [PMID: 33888254 DOI: 10.1016/j.jacc.2021.02.056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Welch CL, Chung WK. Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension. Genes (Basel) 2020;11:E1213. [PMID: 33081265 DOI: 10.3390/genes11101213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]